Washington - Timely diagnosis of juvenile dermatomyositis is critical because early aggressive management with immunosuppressive agents, even for patients with amyopathic disease, is the best method for preventing calcinosis that is a source of significant morbidity for these children, said Amy S. Paller, M.D., at the annual meeting of the American Academy of Dermatology.
Washington - While hair loss may become more acceptable with increasing age, for some older people it is psychologically devastating and adds to the string of losses they may encounter, said Janet L. Roberts, M.D., at the annual meeting of the American Academy of Dermatology.
Washington - Intradermal botulinum toxin type A (Botox) for the treatment of primary axillary hyperhidrosis produces a durable effect, with nearly half of patients requiring only one treatment over a one-year period, according to study data released at the annual meeting of the American Academy of Dermatology here.
Waikoloa, Hawaii - The increase in the number of topical anesthesia options available mandates that dermatologists consider how they compare with respect to efficacy, safety, and patient convenience when selecting an agent to minimize the pain of a cutaneous procedure, said Dina N. Anderson, M.D., at the recent annual Hawaii Dermatology Seminar.
Los Angeles - Use of the topical skin adhesive 2-octylcyanoacrylate (Dermabond, Closure Medical) for final wound closure makes life much easier for surgeons and their patients, said Susan E. Downey, M.D.
Washington - The phrase "what is old is new again" aptly describes the current status of antimicrobial dressings, which, thanks to a new generation of products, are making a comeback in the woundcare arena, said Marketa Limova, M.D., at the annual meeting of the American Academy of Dermatology.
Plans and employers are called to promote health search literacy on the 'Net
Washington - Treatment of melasma has advanced significantly with the availability of new hydroquinone combination therapies that can produce clearing safely and more rapidly than single-agent regimens, said Valerie D. Callender, M.D., at the annual meeting of the American Academy of Dermatology.
From skin cancer drug studies to foot exams, patient and physician awareness of melanoma is key to quick detection of dreaded disease
Periungual warts require accurate diagnosis; aggressive treatment
Washington - Treatment of melasma has advanced significantly with the availability of new hydroquinone combination therapies that can produce clearing safely and more rapidly than single-agent regimens, said Valerie D. Callender, M.D., at the annual meeting of the American Academy of Dermatology.
Doctor comes to correct conclusion using tests, not just visual assessment
Washington -Timely diagnosis of juvenile dermatomyositis is critical because early, aggressive management with immunosuppressive agents, even for patients with amyopathic disease, is the best method for preventing calcinosis, which is a source of significant morbidity for these children, said Amy S. Paller, M.D., at the annual meeting of the American Academy of Dermatology.
Washington - Oral tazarotene has sustained efficacy in the treatment of moderate to very severe plaque psoriasis with no cumulative toxicity. Alan Menter, M.D., presented data from a one-year, open-label study at the 62nd annual meeting of the American Academy of Dermatology.
Overlap strategy can ease transition, preserve stabilitywhen shifting from methotrexate to alefacept therapy
Washington -- Oral tazarotene (Tazorac; Allergan Inc., Irvine, Calif.,) gives patients with plaque psoriasis significant improvements that continue after treatment stops, according to a poster study presented at this year's annual meeting of the American Academy of Dermatology. The blinded, placebo-controlled, multicenter study of about 700 patients shows that oral tazarotene delivers several advantages over existing treatment alternatives.
In a continuing series from Dermatology Times , a panel of pediatric masters discusses treatment options for specific and unusual cases. This second case is that of a 13-year-old girl who presents a progressive area of alopecia over the frontal parietal scalp. There is an ivory scleratic plaque with an extension to the forehead. What do you do?
Isotretinoin still falling in the hands of pregnant women
Vitamin therapy, sunscreen help protect skin from ultraviolet radiation and free radicals
Reports summarizetreatment options,possible thyroid link
Recent literature on pyoderma gangrenosum suggestspotential roles for ANCA screening, infliximab treatment
The long-standing controversy over isotretinoin and its impact on birth defects has now been extended to the debate over whether the importation of prescription drugs from foreign Internet sources, such as Canada, should be legalized.
National report - Aware of a shortage of medical personnel in the Philadelphia region, physician assistant Abby Jacobson was confident she would easily land a new job when she found out her supervising physician was selling his practice. She not only got a new position within a few weeks at a dermatology practice, but she received a salary increase, and negotiated a four-day workweek with Fridays off.
Maui, Hawaii - Some insurers are reluctant to pay for the new biologic drugs for psoriasis, despite the approval of two of the drugs by the U.S. Food and Drug Administration, according to William Abramovits, M.D.
Aastrom Biosciences Inc. announced that it has received a Phase I Small Business Innovation Research Grant (SBIR) grant from the National Institutes of Health National Cancer Institute to develop an immunotherapeutic treatment of malignant melanoma using its AastromReplicell System cell production technology.
Source: www.drugfacts.com United Research Laboratories / Mutual Pharmaceutical Co. announced the launch of a generic version of CollaGenex Pharmaceutical Inc.?s Periostat (doxycycline hyclate) tablets.
Source: www.pharmalive.com Maxim Pharmaceuticals announced that its treatment protocol to provide its investigational drug Ceplene, in combination with interleukin-2 (IL-2), for treatment of patients with advanced malignant melanoma, has been approved by the FDA. The protocol allows Maxim to provide expanded access of Ceplene to patients in the United States while a Phase III clinical trial continues.
Source: www.biotechnologyhealthcare.com Austin, Texas ? Introgen Therapies announced initiation of a Phase II clinical trial of INGN 241 in patients with metastatic melanoma.
Source: www.PRNewswire.com Connetics Corp., a specialty pharmaceutical company focused on dermatology announced Thursday, April 8 that it has received confirmation that the FDA has accepted for filing the company's NDA for Extina, as of Jan. 26, 2004, with a user fee goal date of Sept. 24, 2004.
To protect against the threat of counterfeit drugs, the Food and Drug Administration wants drug makers, distributors, and pharmacists to adopt new technologies, including embedded computer chips that wound transmit identifying information, by 2007.
